The Country Health Profiles are an important step in the European Commission’s two-year State of Health in the EU cycle and are the result of joint work between the OECD and the European Observatory on Health Systems and Policies. The concise, policy relevant profiles are based on a transparent, consistent methodology, using both quantitative and qualitative data, yet flexibly adapted to the context of each EU Member State.
English, PDF, 339kb
The health system in Spain stands out for its impressive life gains during the past decades. Across OECD countries, Spain currently ranks second in terms of life expectancy at birth and at 65 years old, only behind Japan. However, factors such as a high share of out of pocket spending or a relatively low level of health professionals continue to impair higher health system performance.
English, PDF, 781kb
Spain ranks first in terms of life expectancy across all 28 EU countries, following steady gains over the past decades. However, more than half of the remaining years of life of Spanish people at age 65 years are lived with some health problems and disabilities, increasing the demands on health and long-term care systems.
English, PDF, 804kb
España se sitúa en primer lugar respecto a la esperanza de vida por delante del resto de 28 países europeos, tras mejoras estables en las últimas décadas. A pesar de esto, más de la mitad de los años vividos a partir de los 65 años se viven con algún tipo de problema de salud o discapacidad, lo que aumenta la presión en los sistemas de salud y los cuidados a largo plazo.
The global economic crisis has had a profound impact on people’s well-being, reaching far beyond the loss of jobs and income, and affecting citizens’ satisfaction with their lives and their trust in governments, according to a new OECD report.
The mortality amenable to health care is defined as a possible indicator to measure the health care systems performance in preventing premature deaths that can be avoided by appropriate health care intervention. This paper assesses the feasibility of using this indicator in OECD countries.
This publication examines the innovation system in pharmaceutical biotechnology in eight OECD countries. Based on rich evidence, it draws policy recommendations to foster innovation in biopharmaceuticals advocating an integrated policy approach.